Clinical Trial Update: Tepilta® Versus Oxetacaine, Antacids and Placebo [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Tepilta® to oxetacaine, antacids and placebo in radiation-induced oesophagitis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Radiation-induced Oesophagitis

Drugs mentioned

• Oxetacaine (oxetacaine)
• Tepilta® (null)

Snippet

Sponsor: MEDA Pharma GmbH & Co. KG | Conditions: Radiation-induced Oesophagitis | Phase 3 | Status: TERMINATED